View Item 

Show simple item record

Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations

dc.contributor.authorScheiman, James M.en_US
dc.contributor.authorCryer, B.en_US
dc.contributor.authorAsaka, M.en_US
dc.contributor.authorBerenbaum, F.en_US
dc.contributor.authorBonnet, J.en_US
dc.contributor.authorChan, Francis K. L.en_US
dc.contributor.authorKrejs, G.en_US
dc.contributor.authorLanas, Angelen_US
dc.contributor.authorWeaver, A.en_US
dc.contributor.authorZerbib, F.en_US
dc.date.accessioned2010-06-01T21:30:10Z
dc.date.available2010-06-01T21:30:10Z
dc.date.issued2005-09en_US
dc.identifier.citationSCHEIMAN, J. M.; CRYER, B.; ASAKA, M.; BERENBAUM, F.; BONNET, J.; CHAN, F. K.-L.; KREJS, G.; LANAS, A.; WEAVER, A.; ZERBIB, F. (2005). "Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations." Alimentary Pharmacology & Therapeutics Symposium Series 1(1): 26-32. <http://hdl.handle.net/2027.42/74559>en_US
dc.identifier.issn1746-6334en_US
dc.identifier.issn1746-6342en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74559
dc.format.extent74606 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2005 Blackwell Publishing Ltden_US
dc.titlePanel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendationsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationother* Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japanen_US
dc.contributor.affiliationother† Faculty of Medicine Pierre and Marie Curie, Department of Rheumatology, Saint-Antoine Hospital, Paris, Franceen_US
dc.contributor.affiliationother† Cardiology and Vascular Diseases Department, Victor Segalen University, Bordeaux, Franceen_US
dc.contributor.affiliationother§ Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Chinaen_US
dc.contributor.affiliationother¶ Karl-Franzens University, Graz, Austriaen_US
dc.contributor.affiliationother** Gastroenterology Department, HCU, Instituto Aragones de Ciencias de la Salud (Red C03/02), Zaragoza, Spainen_US
dc.contributor.affiliationother†† University of Nebraska Medical Center, Omaha, NE, USAen_US
dc.contributor.affiliationother†† Department of Gastroenterology, Saint-Andre Hospital, Bordeaux, Franceen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74559/1/j.1746-6342.2005.00018.x.pdf
dc.identifier.doi10.1111/j.1746-6342.2005.00018.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeutics Symposium Seriesen_US
dc.identifier.citedreference1 Heartwire News. February 19, 2005, http://www.theheart.org.en_US
dc.identifier.citedreferenceCatella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809 – 17.en_US
dc.identifier.citedreferenceJuni P, Nartey L, Reichenbach L, et al. Risk of cardiovascular events with rofecoxib: cumulative meta-analysis. Lancet 2004; 364 ( 9450 ): 2021 – 9.en_US
dc.identifier.citedreference4 FDA Press Release. April, 2005, http://www.fda.gov/cder/drug/advisory/COX2.htm.en_US
dc.identifier.citedreferenceBresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092 – 102.en_US
dc.identifier.citedreferenceLÉvesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481 – 9.en_US
dc.identifier.citedreferenceSolomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071 – 80.en_US
dc.identifier.citedreferenceGabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787 – 96.en_US
dc.identifier.citedreferenceGarcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769 – 72en_US
dc.identifier.citedreferenceSilverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241 – 9.en_US
dc.identifier.citedreferenceHuang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14 – 22.en_US
dc.identifier.citedreferenceChan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004; 19: 1051 – 61.en_US
dc.identifier.citedreferenceTaha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435 – 9.en_US
dc.identifier.citedreferenceHooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J 2004; 329: 948.en_US
dc.identifier.citedreferenceHayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161 – 72.en_US
dc.identifier.citedreferencePearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388 – 91.en_US
dc.identifier.citedreferenceHutchison TA, Shahan DR, Anderson ML, eds. Drugdex® System. Englewood, CO: Micromedex Inc.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1746-6342.2005.00018.x.pdf
Size:
72.85KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.